Technical Analysis for VERV - Verve Therapeutics, Inc.

Grade Last Price % Change Price Change
F 14.42 0.49% 0.07
VERV closed up 0.49 percent on Friday, March 24, 2023, on 83 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Lower Bollinger Band Walk Weakness 0.49%
Wide Bands Range Expansion 0.49%
Below Lower BB Weakness 0.49%
Lower Bollinger Band Touch Weakness 0.49%
Oversold Stochastic Weakness 0.49%
Below Lower BB Weakness -5.26%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% about 9 hours ago
60 Minute Opening Range Breakout about 14 hours ago
Rose Above Lower Bollinger Band about 14 hours ago
Down 3% about 14 hours ago
Down 2 % about 14 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Verve Therapeutics, Inc. Description

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease


Sector: Healthcare
Industry: Biotechnology
Keywords: Cardiovascular Disease Lipid Cholesterol Hypercholesterolemia Low Density Lipoprotein Pcsk9

Is VERV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 43.0
52 Week Low 10.7
Average Volume 708,399
200-Day Moving Average 25.39
50-Day Moving Average 19.97
20-Day Moving Average 17.44
10-Day Moving Average 16.28
Average True Range 1.19
RSI 28.57
ADX 21.31
+DI 13.53
-DI 34.40
Chandelier Exit (Long, 3 ATRs) 17.39
Chandelier Exit (Short, 3 ATRs) 17.39
Upper Bollinger Bands 20.53
Lower Bollinger Band 14.34
Percent B (%b) 0.01
BandWidth 35.51
MACD Line -1.39
MACD Signal Line -1.15
MACD Histogram -0.2464
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.56
Resistance 3 (R3) 15.48 15.03 15.37
Resistance 2 (R2) 15.03 14.74 15.07 15.31
Resistance 1 (R1) 14.72 14.56 14.88 14.80 15.24
Pivot Point 14.27 14.27 14.34 14.31 14.27
Support 1 (S1) 13.96 13.98 14.12 14.04 13.60
Support 2 (S2) 13.51 13.80 13.55 13.53
Support 3 (S3) 13.20 13.51 13.47
Support 4 (S4) 13.28